IP Library Granted Patent US 11,534,429
Granted Patent B2
US 11,534,429 · App. 17/389,748 · Granted Dec 27, 2022

Small molecule inhibitors of bacterial efflux pumps and methods of using same

Inventors: Abigail L. Reens (Boulder, CO); Amy L. Crooks (Erie, CO); Corrella S. Detweiler (Boulder, CO)
Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
A61K31/426A61K31/506A61K31/517A61K31/65A61K38/12C12Q1/18G01N33/502G01N33/5055G01N2333/255
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,534,429
App. No.
17/389,748
Granted
Dec 27, 2022
Kind
B2
Abstract

An empirical Screen for Anti-infectives using Fluorescence microscopy of IntracellulaR Enterobacteriaceae (SAFIRE) was developed. Using this methodology, a library of small molecules and identified antimicrobials that are cell permeable and non-host-toxic were screened. Inhibitors of bacterial efflux pumps were identified as being implicated in antibiotic resistance and are attractive therapeutic targets for antimicrobials.

Claims (20)

1. A method of identifying an anti-infective compound with activity against intracellular pathogens, the method comprising:

(a) providing a first subset of cells and a second subset of cells;

(b) infecting the first subset of cells and the second subset of cells with a marker-producing bacteria;

(c) staining the first subset of cells with a vitality marker;

(d) obtaining a first value of cellular infectivity;

(e) contacting the second subset of cells with an anti-infective compound;

(f) staining the second subset of cells with a vitality marker;

(g) obtaining a second value of cellular infectivity; and

(h) comparing the first value of cellular infectivity to the second value of cellular infectivity; and

(i) identifying an anti-infective compound, wherein the anti-infective compound is identified when the second value of cellular infectivity is decreased compared to the first value of cellular infectivity.

2. The method of claim 1 , wherein the first and second values of cellular infectivity are obtained by quantifying cells in the first subset of cells and the second subset of cells using fluorescent microscopy.

3. The method of claim 1 , wherein the marker-producing bacteria express green fluorescent protein.

4. The method of claim 1 , wherein the marker-producing bacteria is Gram-negative intracellular pathogen.

5. The method of claim 4 , wherein the Gram-negative intracellular pathogen is a species of the genus Salmonella.

6. The method of claim 5 , wherein the Salmonella species is enterica serovar Typhimurium (S.Tm).

7. The method of claim 4 , wherein the Gram-negative intracellular pathogen is Klebsiella pneumoniae, Enterobacter cloacae , or Escherichia coli.

8. The method of claim 1 , wherein the marker-producing bacteria is Gram-positive intracellular pathogen.

9. The method of claim 1 , wherein the first subset of cells and the second subset of cells are macrophages.

10. The method of claim 1 , wherein the first subset of cells and the second subset of cells are HeLa cells.

11. The method of claim 1 , wherein the anti-infective compound is identified when the second value of cellular infectivity is decreased by at least 25% compared to the first value of cellular infectivity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 6, 2023
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065790/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: REENS, ABIGAIL L; CROOKS, AMY L.; DETWEILER, CORRELLA S.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 057032/0510 →
Continuity (3)
Division 16497315
Provisional Application 62477175 · Mar 27, 2017
Related Publication 20220175736A1 · Jun 9, 2022